KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy. Subjects should have documented progressive disease during prior treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy.Subjects will be randomized to two treatment groups in a 1:1 ratio.

Treatment Group: KN046 5mg/kg Q3W + lenvatinib recommended for phase III dose (RP3D) every day.

Control group: Docetaxel 75mg/m2 Q3W .
Advanced Non-small Cell Lung Cancer
BIOLOGICAL: KN046|DRUG: Lenvatinib|DRUG: Docetaxel
DLT, Dose limit toxicity (phase 2), 28 days or 21 days|OS, Overall survival (OS) was defined as the time from randomization to death due to any cause (phase 3)., up to 2 years|PFS, Progression-free survival (PFS) was defined as the time from randomization grouping to the first documented disease progression or death from any cause as evaluated by the investigator according to RECIST 1.1 criteria (phase 3)., up to 2 years
ORR, Objective response rate (ORR) based on the RECIST 1.1 by principal investigator, up to 2 years|DCR, Disease control rate (DCR) based on the RECIST 1.1 by principal investigator, up to 2 years|DOR, Duration of response (DOR) based on the RECIST 1.1 by principal investigator, up to 2 years|CBR, Clinical benefit rate (CBR) based on the RECIST 1.1 by independent review committee, up to 2 years|TTR, Time to response (TTR) based on the RECIST 1.1 by independent review committee, up to 2 years
Safety endpoint, Serious adverse events (SAE), changes and abnormal findings in laboratory test, vital sign and physical examination., up to 2 years
This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy. Subjects should have documented progressive disease during prior treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy.Subjects will be randomized to two treatment groups in a 1:1 ratio.

Treatment Group: KN046 5mg/kg Q3W + lenvatinib recommended for phase III dose (RP3D) every day.

Control group: Docetaxel 75mg/m2 Q3W .